pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

armagen PRESS RELEASE ARCHIVE

Apr 27, 2020

JCR Pharmaceuticals announces Completion of Acquisition of ArmaGen, Inc.

Aug 2, 2018

ArmaGen Receives U.S. Orphan Drug Designation for AGT-184

Jul 10, 2018

ArmaGen's AGT-181 52-Week Phase 1/2 Proof-of-Concept Study Results Published in Orphanet Journal of Rare Diseases

Feb 8, 2018

ArmaGen's AGT-181 Demonstrates Neurocognitive Benefit in Children with Severe MPS I

Nov 30, 2017

ArmaGen's AGT-181 Granted Fast Track Designation for the Treatment of Hurler Syndrome (MPS I)

Feb 7, 2017

ArmaGen Announces Oral Presentation of Preliminary Results from its Phase 2 Clinical Trial of AGT-181 in Patients with MPS 1 to be Presented at WORLDSymposium 2017

Jan 19, 2017

ArmaGen Appoints Mathias Schmidt, Ph.D., as Chief Executive Officer

Jul 14, 2016

ArmaGen Presents Data from First Cohort of Phase 1/2a of AGT-182 for Treatment of Hunter Syndrome

Jul 8, 2016

Metachromatic Leukodystrophy (MLD) - Pipeline Review 2016 Featuring ArmaGen, GlaxoSmithKline, RegenxBio and Shire - Research and Markets

Jul 7, 2016

ArmaGen and Rett Syndrome Research Trust Collaborate to Develop Novel Therapeutic for the Treatment of Rett Syndrome

Mar 31, 2016

ArmaGen Announces Initiation of Phase 2 Proof-of-Concept Clinical Trial in Brazil to Study AGT-181 for the Treatment of Hurler Syndrome

Sep 2, 2015

ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome

Apr 8, 2015

ArmaGen Announces FDA Acceptance of IND Application for AGT-181 for the Treatment of Hurler Syndrome

Mar 10, 2015

PacificGMP and ArmaGen Announce Successful Manufacture of ArmaGen's investigational enzyme replacement therapies, AGT-182 and AGT-181, for Phase 1 Clinical Trial

Dec 11, 2014

ArmaGen Announces FDA Acceptance of IND Application for AGT-182 for the Treatment of Hunter Syndrome

Dec 3, 2014

ArmaGen to Present at Oppenheimer 25th Annual Healthcare Conference

Jul 23, 2014

ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome

Jun 17, 2014

ArmaGen Receives Notice of Allowance for U.S. Patent Covering Novel Investigational Therapy for Hunter Syndrome

Sep 4, 2013

ARMAGEN Expands Patent Portfolio With Issuance Of Two Additional U.S. Patents

Jul 18, 2013

ARMAGEN Receives US Orphan Designation For Lead Product AGT-182

Jan 3, 2013

ArmaGen Technologies, Inc. Hires Biotech Executive as CEO

Nov 29, 2012

ArmaGen Technologies, Inc. Announces $17 Million Series A Financing

Google Analytics Alternative